Akebia Therapeutics, Inc. - Understand $akba stock

$AKBA Market Cap: $442.9 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$169.9M

TTM

Gross Margin

67.2%

TTM

Net Earnings

-$45.99M

TTM

Current Assets

$100.1M

Q3 2024

Current Liabilities

$65.71M

Q3 2024

Current Ratio

152.37%

Q3 2024

Total Assets

$207.1M

Q3 2024

Total Liabilities

$257.5M

Q3 2024

Book Value

-$50.40M

Q3 2024

Cash

$34.02M

Q3 2024

P/E

-9.630

Nov 29, 2024 EST

Free Cash Flow

-$19.10M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$194.6M	$292.6M	$213.6M	$295.3M	$335.0M	$207.7M	$181.2M	$1.535M	$0.00	$0.00	$1.050M	$1.971M	$0.00
YoY Change	-33.49%	37.0%	-27.68%	-11.85%	61.26%	14.63%	11706.32%			-100.0%	-46.74%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$194.6M	$292.6M	$213.6M	$295.3M	$335.0M	$207.7M	$181.2M	$1.535M	$0.00	$0.00	$1.050M	$1.971M	$0.00
Cost Of Revenue	$39.74M	$84.80M	$153.4M	$295.9M	$145.3M	$7.768M	$0.00
Gross Profit	$154.9M	$207.8M	$60.18M	-$601.0K	$189.7M	$200.0M	$181.2M
Gross Profit Margin	79.58%	71.02%	28.18%	-0.2%	56.62%	96.26%	99.99%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$100.2M	$138.7M	$174.2M	$153.9M	$149.5M	$87.06M	$27.01M	$22.21M	$18.50M	$12.50M	$5.200M	$2.900M	$2.600M
YoY Change	-27.73%	-20.36%	13.13%	3.01%	71.67%	222.35%	21.6%	20.05%	48.0%	140.38%	79.31%	11.54%
% of Gross Profit	64.72%	66.74%	289.38%		78.8%	43.54%	14.91%
Research & Development	$63.08M	$129.1M	$147.9M	$218.5M	$323.0M	$291.0M	$230.9M	$115.8M	$43.02M	$23.26M	$8.902M	$5.632M	$13.00M
YoY Change	-51.14%	-12.67%	-32.33%	-32.35%	10.98%	26.04%	99.42%	169.17%	84.91%	161.32%	58.06%	-56.68%
% of Gross Profit	40.73%	62.13%	245.67%		170.28%	145.52%	127.42%
Depreciation & Amortization	$37.63M	$1.654M	$1.927M	$2.075M	$2.245M	$899.0K	$617.0K	$296.0K	$96.00K	$49.00K	$1.000K	$0.00	$40.00K
YoY Change	2174.91%	-14.17%	-7.13%	-7.57%	149.72%	45.71%	108.45%	208.33%	95.92%	4800.0%		-100.0%
% of Gross Profit	24.29%	0.8%	3.2%		1.18%	0.45%	0.34%
Operating Expenses	$199.4M	$286.9M	$325.5M	$375.8M	$476.0M	$378.1M	$257.9M	$138.0M	$61.51M	$37.94M	$15.93M	$8.523M	$15.50M
YoY Change	-30.52%	-11.85%	-13.39%	-21.03%	25.87%	46.62%	86.89%	124.33%	62.13%	138.12%	86.94%	-45.01%
Operating Profit	-$44.47M	-$79.12M	-$265.3M	-$376.4M	-$286.3M	-$178.2M	-$76.67M	-$136.5M	-$61.51M	-$37.94M	-$15.93M	-$8.523M
YoY Change	-43.78%	-70.18%	-29.52%	31.49%	60.69%	132.36%	-43.81%	121.84%	62.13%	138.12%	86.94%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	-$6.032M	-$15.69M	-$19.94M	-$8.871M	$792.0K	$6.154M	$2.799M	$901.0K	$510.0K	$200.0K	-$700.0K	-$1.600M	$0.00
YoY Change	-61.55%	-21.31%	124.73%	-1220.08%	-87.13%	119.86%	210.65%	76.67%	155.0%	-128.57%	-56.25%
% of Operating Profit
Other Income/Expense, Net	$887.0K	$3.146M	$2.414M	$1.856M	-$794.0K	$81.00K	$204.0K	-$188.0K	$287.0K	$700.0K	$1.000M	$2.000M	$200.0K
YoY Change	-71.81%	30.32%	30.06%	-333.75%	-1080.25%	-60.29%	-208.51%	-165.51%	-59.0%	-30.0%	-50.0%	900.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$51.93M	-$92.56M	-$282.8M	-$383.5M	-$286.3M	-$171.9M	-$73.67M	-$135.7M	-$60.70M	-$37.00M	-$13.20M	-$8.200M	-$15.30M
YoY Change	-43.9%	-67.27%	-26.24%	33.94%	66.52%	133.37%	-45.73%	123.64%	64.05%	180.3%	60.98%	-46.41%
Income Tax		$0.00	$0.00	$0.00	-$6.631M	-$28.34M	$0.00				$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$51.93M	-$92.56M	-$282.8M	-$383.5M	-$279.7M	-$143.6M	-$73.67M	-$135.7M	-$60.72M	-$37.03M	-$13.17M	-$8.196M	-$15.30M
YoY Change	-43.9%	-67.27%	-26.24%	37.12%	94.76%	94.9%	-45.73%	123.58%	63.95%	181.26%	60.65%	-46.43%
Net Earnings / Revenue	-26.68%	-31.63%	-132.43%	-129.85%	-83.48%	-69.12%	-40.65%	-8843.45%			-1254.2%	-415.83%
Basic Earnings Per Share	-$0.28	-$0.51	-$1.70	-$2.77	-$2.36
Diluted Earnings Per Share	-$0.28	-$0.51	-$1.70	-$2.77	-$2.36	-$2.476M	-$1.694M	-$3.599M	-$2.291M	-$2.403M	-$721.3K	-$448.1K	-$836.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$42.93M	$90.47M	$149.8M	$268.7M	$147.7M	$321.6M	$317.8M	$260.3M	$138.5M	$108.9M	$32.60M	$1.600M	$6.400M
YoY Change	-52.55%	-39.61%	-44.25%	81.92%	-54.07%	1.2%	22.09%	87.94%	27.18%	234.05%	1937.5%	-75.0%
Cash & Equivalents	$42.93M	$90.47M	$149.8M	$228.7M	$147.4M	$104.6M	$70.20M	$187.3M	$49.80M	$32.80M	$21.20M	$1.600M	$5.000M
Short-Term Investments			$0.00	$40.00M	$200.0K	$217.0M	$247.6M	$73.00M	$88.70M	$76.10M	$11.30M	$0.00	$1.400M
Other Short-Term Assets	$20.24M	$33.54M	$33.14M	$14.90M	$6.600M	$15.70M	$6.300M	$2.200M	$2.600M	$1.500M	$700.0K	$500.0K	$800.0K
YoY Change	-39.65%	1.21%	122.42%	125.76%	-57.96%	149.21%	186.36%	-15.38%	73.33%	114.29%	40.0%	-37.5%
Inventory	$15.69M	$21.76M	$38.20M	$61.00M	$116.3M	$114.2M
Prepaid Expenses
Receivables	$39.29M	$39.18M	$50.88M	$26.90M	$38.90M	$16.70M	$34.20M	$33.80M		$0.00	$100.0K	$100.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$118.1M	$184.9M	$272.0M	$371.4M	$309.5M	$468.3M	$358.4M	$296.3M	$141.0M	$110.5M	$33.40M	$2.200M	$7.200M
YoY Change	-36.12%	-32.01%	-26.76%	20.0%	-33.91%	30.66%	20.96%	110.14%	27.6%	230.84%	1418.18%	-69.44%
Property, Plant & Equipment	$16.05M	$34.37M	$40.61M	$35.50M	$39.40M	$8.000M	$3.600M	$2.600M	$500.0K	$200.0K	$0.00	$0.00	$0.00
YoY Change	-53.32%	-15.35%	14.38%	-9.9%	392.5%	122.22%	38.46%	420.0%	150.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$12.42M	$5.372M	$49.75M	$38.00M	$76.00M	$137.0M	$2.300M	$1.300M	$1.400M	$300.0K	$1.200M
YoY Change	131.25%	-89.2%	30.93%	-50.0%	-44.53%	5856.52%	76.92%	-7.14%	366.67%	-75.0%
Total Long-Term Assets	$123.6M	$166.9M	$253.5M	$272.7M	$461.7M	$528.2M	$5.800M	$3.900M	$1.900M	$500.0K	$1.300M	$0.00	$0.00
YoY Change	-25.96%	-34.18%	-7.03%	-40.94%	-12.59%	9006.9%	48.72%	105.26%	280.0%	-61.54%
Total Assets	$241.7M	$351.8M	$525.5M	$644.1M	$771.2M	$996.5M	$364.2M	$300.2M	$142.9M	$111.0M	$34.70M	$2.200M	$7.200M
YoY Change
Accounts Payable	$14.64M	$18.02M	$33.59M	$41.30M	$39.20M	$42.80M	$7.000M	$2.000M	$2.300M	$2.000M	$700.0K	$400.0K	$1.400M
YoY Change	-18.79%	-46.35%	-18.67%	5.36%	-8.41%	511.43%	250.0%	-13.04%	15.0%	185.71%	75.0%	-71.43%
Accrued Expenses	$67.74M	$71.00M	$104.5M	$130.6M	$129.1M	$150.9M	$51.50M	$30.30M	$9.600M	$4.900M	$3.200M	$400.0K	$400.0K
YoY Change	-4.59%	-32.03%	-20.02%	1.16%	-14.45%	193.01%	69.97%	215.63%	95.92%	53.13%	700.0%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$15.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change					-100.0%
Long-Term Debt Due	$17.50M	$32.00M	$97.54M		$0.00						$0.00
YoY Change	-45.31%	-67.19%
Total Short-Term Liabilities	$99.87M	$124.8M	$256.5M	$187.1M	$208.1M	$265.7M	$141.1M	$114.3M	$11.90M	$6.900M	$3.900M	$4.900M	$1.800M
YoY Change	-19.95%	-51.36%	37.09%	-10.09%	-21.68%	88.31%	23.45%	860.5%	72.46%	76.92%	-20.41%	172.22%
Long-Term Debt	$17.18M	$34.08M	$0.00	$96.40M	$75.80M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-49.58%		-100.0%	27.18%
Other Long-Term Liabilities	$155.2M	$183.7M	$192.6M	$113.0M	$92.50M	$88.30M	$100.6M	$117.8M	$100.0K	$0.00		$0.00	$0.00
YoY Change	-15.47%	-4.65%	70.44%	22.16%	4.76%	-12.23%	-14.6%	117700.0%
Total Long-Term Liabilities	$172.4M	$217.7M	$192.6M	$209.4M	$168.3M	$88.30M	$100.6M	$117.8M	$100.0K	$0.00	$0.00	$0.00	$0.00
YoY Change	-20.81%	13.05%	-8.02%	24.42%	90.6%	-12.23%	-14.6%	117700.0%
Total Liabilities	$272.3M	$342.5M	$449.1M	$396.5M	$376.4M	$360.6M	$241.7M	$232.1M	$11.90M	$6.900M	$3.900M	$4.900M	$1.800M
YoY Change	-20.5%	-23.74%	13.26%	5.34%	4.38%	49.19%	4.14%	1850.42%	72.46%	76.92%	-20.41%	172.22%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	187.5M shares	182.8M shares	165.9M shares	138.5M shares	118.4M shares
Diluted Shares Outstanding	187.5M shares	182.8M shares	165.9M shares	138.5M shares	118.4M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $442.91 Million

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 167 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). The company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Industry: Pharmaceutical Preparations Peers: AQUABOUNTY TECHNOLOGIES INC Atreca, Inc. BIOVIE INC. Unity Biotechnology, Inc. Disc Medicine, Inc. GT Biopharma, Inc. EOM Pharmaceutical Holdings, Inc. PALATIN TECHNOLOGIES INC Solid Biosciences Inc.